Slide 1: Corporate Presentation: Unlocking The Potential Of Advanced Therapies For Hearing Loss
Corporate Presentation Unlocking The Potential Of Advanced Therapies For Hearing Loss June 2026
Slide 2: Disclaimer
DISCLAIMER • This document has been prepared by Sensorion (the “Company”) and is provided for information • This document contains certain forward-looking statements. These statements are not guarantees purposes only. This document does not purport to contain comprehensive or complete information of
Slide 3: Sensorion vision
1 SENSORION Our vision is to enable people with inner ear hearing disorders to live life with unlimited connections 3
Slide 4: Establishing global leadership in hearing loss supported by deep expertise
Sensorion Establishing global leadership in hearing loss supported by deep expertise • Unmet clinical need: 1.5bn people affected by hearing loss (HL) • Multiple causes: genetic, environmental, idiopathic • Modality agnostic approach to hearing loss disorders • World-leading and exclusive partnershi
Slide 5: Experienced leadership team, Board of Directors and SAB
Sensorion Experienced leadership team, Board of Directors and SAB FRED CHEREAU LAURENE DANON BERND SCHMIDT STEPHANIE FILIPE LAURENT DESIRE VALÉRIE SALENTEY Chief Executive Officer Finance CMC Business Ops & Portfolio Preclinical Clinical & Regulatory SENSORION Management (Since 2026) SENSORION SENSO
Slide 6: In-house and partners capabilities
Sensorion Best-in-class partners and internal capabilities to transform standard of care TRANSLATIONAL CLINICAL DIAGNOSIS AND RESEARCH RESEARCH PATIENT JOURNEY PARTNERS GLOBAL CLINICAL CENTERS OF EXCELLENCE IN-HOUSE PRECLINICAL - CLINICAL EXPERIENCE CMC GENE THERAPY REGULATORY EXPERTISE PATIENT ACCE
Slide 7: Portfolio of advanced hearing loss therapies
Sensorion Portfolio of advanced hearing loss therapies Product Indication Discovery In-vivo POC Preclinical Phase 1 Phase 2 Phase 3 Next steps CTA filed (Canada, SENS-601* HL related to GJB2 mutations Phase 1/2 France) | US IND and GENE THERAPIES (GJB2-GT) Congenital Onset Australia in preparation R
Slide 8: Restore GJB2-Related Hearing Loss
2 RESTORE GJB2-RELATED HEARING LOSS 8
Slide 9: Why the inner ear is ideally suited for gene therapy
Gene Therapy in the Inner Ear: Why the inner ear is ideally suited for gene therapy • Confined, fluid-filled organ enabling direct local administration to target cells, no systemic exposure required • Demonstrated limited biodistribution outside the target organ • Inner ear naturally immunologically
Slide 10: Sensorion: a differentiated position, built on clinical experience
Gene Therapy in the Inner Ear: Sensorion: a differentiated position, built on clinical experience • Differentiated GT product with high target cell specificity, efficient transduction, and limited off-target biodistribution • In-house non-GMP development laboratories enabling AAV process development
Slide 11: SENS-601 targets GJB2-related hearing loss
Sensorion SENS-601 targets GJB2-related hearing loss: the most common cause of genetic deafness PROGRAM RESULTING FROM THE INSTITUT PASTEUR COLLABORATION GJB2-RELATED HEARING LOSS PATIENT POPULATION We have identified three forms of hearing loss associated with GJB2 gene mutations: ~200,000 congenit
Slide 12: Dedicated surgical approach for gene therapy
SENS-601 Gene Therapy Dedicated surgical approach for gene therapy Surgical Approach – Injection System • Surgical procedure is similar to cochlear Combining 2 common implantation and well mastered by ENT surgical techniques: surgeons cochlear implant and stapedotomy • No overpressure • Optimized su
Slide 13: Connexin 26 is encoded by GJB2 gene
SENS-601 Connexin 26 is encoded by GJB2 gene and is responsible for tissue homeostasis Mutations In The GJB2 gene Lead To Deafness GJB2 Expression In The Cochlea • Connexin 26 and Connexin 30 proteins are the dominating connexins in the cochlea; heteromeric or heterotypic hexamers forming Gap Juncti
Slide 14: Lead candidate selected to answer specific development criteria
SENS-601 Lead candidate was selected to answer specific development criteria CRITERIA LEAD CANDIDATE Natural and synthetic AAV capsid libraries screening for broad coverage of target cells Expression cassette design for high-level of target cells transduction, correct cellular localization, active g
Slide 15: Lead candidate delivers Connexin 26 in target cells
SENS-601 Lead candidate can deliver Connexin 26 in the appropriate target cells Correct Delivery Of Connexin 26 Using Lead Candidate Flag In Non-Human Primate Cochlea Cell Types Claudius Cells Deiters Cells Great Epithelial Ridge Cells Hensen Cells Inner Border Cells Inner Hair Cells Inner Phalangea
Slide 16: SENS-601 transduction leads to functional CX26 hemichannels
SENS-601 SENS-601 transduction leads to functional CX26 hemichannels at the cell membrane Functional Hemichannel Permeability Assay SENS-601 Rescues Cx26 Protein Function Even In Cx26 Mutant Contexts Propidium Iodide (PI) is a fluorescent dye that cannot cross intact cell membranes 35delG M34T V37I
Slide 17: Exclusive GJB2 cKO mouse model relevant to DFNB1A
SENS-601 Exclusive GJB2 cKO mouse model highly relevant to DFNB1A with severe/profound hearing loss - Biallelic GJB2 inactivation to mimic the most common form of DFNB1A Gjb2 cKO Mouse Model Large CX26 Depletion Presence of Hair Cells Allows For Therapeutic Intervention Profound/severe hearing loss
Slide 18: Lead candidate improves hearing loss and restores CX26 network in mouse model
SENS-601 Lead candidate improves hearing loss and restores CX26 network in DFNB1 mouse model 100 SPL) 100 SPL) 80 (dB 80 (dB 60 Threshold Proof Of Concept In Mice With Congenital 60 Hearing Loss CX26 levels & ABR restoration correlation Threshold 40 40 20 Assessment of CX26 network restoration withi
Slide 19: SENS-601 is safe and well tolerated in mice and NHP
SENS-601 SENS-601 is safe and well tolerated in mice and NHP adequate safety margin demonstrated in combined 3 and 6-month toxicolgy study NHP Toxicology and Biodistribution Study (3-month arm) Mouse Toxicology Study (3-month arm) Unilateral intracochlear administration Intravenous administration •
Slide 20: SENS-601 Program status
SENS-601 Program status Ongoing Ongoing PoC Efficacy CTA* Natural History Natural History submissions in US IND* and CTA and Safety Data Study Study Canada and France Australia* by end of ASGCT 2025 OTOCONEX in SONG with adults (with Fast-track) year 2026 pediatrics *Congenital onset Copyright by Se
Slide 21: SENS-401 Programs
3 SENS-401 PROGRAMS Multiple Indications To Treat And Prevent Hearing Loss 21
Slide 22: SENS-401: A First-in Class Innovation
SENS-401: A First-in Class Innovation Three key indications for treatment and prevention of sensorineural hearing loss • First-in-class small • Protects sensory hair • Orphan Drug Designation molecule targeting Ongoing cells and prevents nerve granted by both EMA and European inner ear lesions degen
Slide 23: Potential to transform life for people with underserved hearing loss diseases
SENS-401 Potential to transform everyday life for people living with underserved hearing loss diseases Positive findings in a Phase 2b subgroup Sudden Sensorineural 115 randomized patients Hearing Loss • Statistically significant complete hearing recovery observed (SSNHL) at Day 84 in 50% of patient
Slide 24: Sensorion vision
4 SENSORION Our vision is to enable people with inner ear hearing disorders to live life with unlimited connections 24
Slide 25: Sensorion newsflow
Sensorion newsflow [estimated timelines] H1 2026 End of 2026 2027 SENS-601 Gene Therapy Program CTA Filing US IND Application First clinical data Ongoing SENS-401 Program Exploring Partnering Opportunities Copyright by Sensorion - 2026 - All Rights Reserved 125
Slide 26: Conclusion
Sensorion Conclusion • Developing hearing loss therapeutics to treat, prevent and restore hearing – an area of high unmet clinical need • Combining extensive internal capabilities with world-leading exclusive partnerships • SENS-601 lead asset entering the clinic shortly, with global development fra
Slide 27: Thank You
THANK YOU E:contact@sensorion-pharma.com
Slide 28: Hearing Loss
HEARING LOSS 28
Slide 29: Access and clarity are mandatory for optimal outcomes
Access and clarity are mandatory for optimal outcomes (Hz) (dB HL) O = Right ear threshold Normal X = Left ear threshold Slight th f p s Mild t Hearing aid fitting range* z v h g k m d b ch j n o sh Moderate i a ng r e u Moderately-severe Severe Cochlear implant candidacy range* Profound *Guideline
Slide 30: Internal Capabilities
Internal Capabilities 30
Slide 31: We have established internal capabilities to ensure successful execution
We have established internal capabilities to ensure successful execution PRECLINICAL - CMC GENE THERAPY PATIENT ACCESS SMALL MOLECULES & CLINICAL EXPERIENCE REGULATORY EXPERTISE FACILITIES GT PROGRAMS • Audiology, inner ear surgery and • 600 subjects enrolled in • Process development: non- • Develop
Slide 32: SENS-401 Programs Back-Up
SENS-401 PROGRAMS Back-Up Multiple Indications To Treat And Prevent Hearing Loss 32
Slide 33: SENS-401 Mechanism Of Action
SENS-401 Mechanism Of Action Disrupted Ca2+ Calcineurin Neurodegenerative cascades INSULT homeostasis Activation Excitotoxicity • NFAT translocation: oxidative stress, survival, inflammation pathways Neuro Inflammation • Cell death pathways: BAD, mPTP, AIF, caspases activation • Structural degenerat
Slide 34: SENS-401 CI: Preservation Of Residual Hearing Following Cochlear Implantation
SENS-401 CI Preservation Of Residual Hearing Following Cochlear Implantation 34 34
Slide 35: SENS-401 to preserve residual hearing after cochlear implantation
CI SENS-401 to preserve residual hearing after cochlear implantation COMBINATION OF COCHLEAR IMPLANT WITH SENS-401 TO PREVENT CELL-DEATH POST COCHLEAR IMPLANT PROCEDURE BURDEN OF DISEASE KEY FIGURES Growing understanding of the link between healthy hearing and healthy ageing ≈ 90,000 Implants sold g
Slide 36: Residual low frequency hearing benefits for cochlear implant users
CI Residual low frequency hearing benefits for cochlear implant users Initial Initial shift* shift* Second shift* (2-4 weeks (2-4 weekspostoperative) postoperative) (3-6 months postoperative) between surgery between andand surgery initial activation initial activationofofthe thedevice device Attribu
Slide 37: SENS-401 CI study design - study completed
CI SENS-401 CI study design - study completed A Phase 2a, Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Presence of SENS-401 in the Perilymph and to Assess Its Efficacy to Prevent Residual Hearing Loss After Cochlear Implantation SCREENING PERIOD EVALUATION PERIOD W-6 W-1 W0
Slide 38: Primary endpoint of the phase 2a study has been met
CI Primary endpoint of the phase 2a clinical study for residual hearing preservation has been met Perilymph Concentrations Data Treated with SENS-401 (n=16) n (%) SENS-401 levels ≤ LLOQ 0 SENS-401 levels > LLOQ 14*(100) *Among the 16 participants who underwent surgery, 15 have a perilymph samples an
Slide 39: SENS-401 provides hearing protection 6 & 14 weeks post-cochlear implantation
CI SENS-401 provides hearing protection 6 & 14 weeks post-cochlear implantation LS Mean change from baseline of hearing threshold Mean of the 3-frequency average (250-750 Hz) hearing values at 6 and 14 weeks post CI threshold values at baseline, 6 weeks and 14 weeks post CI 0 40 10 Treated group (n=
Slide 40: SENS-401 provides residual hearing preservation
CI SENS-401 provides residual hearing preservation* 6 & 14 weeks post-cochlear implantation W6 Post-CI W14 Post-CI Complete: HP>75% Partial: HP of 25 to 75% 3-frequency average (250-750 Hz) 27% 40% 14% 53% 40% 43% 29% • Patients in the SENS-401 treated group are twice as likely to show complete or p
Slide 41: SENS-401 CI final results - conclusion
CI SENS-401 CI final results - conclusion SENS-401 can cross the labyrinthine barrier to target cochlear hair cells in all patients sampled, confirming primary endpoint is met. SENS-401, present in the perilymph fluid, reaches concentrations that are pharmacologically active. A complete hearing pres
Slide 42: SENS-401 CIO: Prevention Of Cisplatin-Induced Ototoxicity
SENS-401 CIO Prevention Of Cisplatin-Induced Ototoxicity 42
Slide 43: Cisplatin damages the inner ear and leads to hearing loss
CIO Cisplatin administration for chemotherapies damages The inner ear and leads to hearing loss, tinnitus and dizziness WHAT IS CIO? Hearing loss caused by cisplatin administration as chemotherapeutic treatment. Risk factors include young age as well as individual and cumulative cisplatin doses. CIO
Slide 44: SENS-401 phase 2a NOTOXIS study design
CIO SENS-401 phase 2a proof-of-concept study NOTOXIS recruitment completed – positive preliminary safety data A Phase 2a, Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Efficacy of SENS-401 to Prevent the Ototoxicity Induced by Cisplatin in Adult Subjects with a Neoplastic Dis
Slide 45: Key takeaways
CIO Key takeaways Cumulative dose of cisplatin is a key factor of ototoxicity severity. SENS-401 has a favorable safety profile when administered continuously for up to 23 weeks in adult patients undergoing cisplatin-based chemotherapy. No statistically significant difference observed between treate
Slide 46: SSNHL: Sudden Sensorineural Hearing Loss
SSNHL Sudden Sensorineural Hearing Loss 46
Slide 47: SSNHL is a severe disease affecting more than 200,000 patients per year
Sudden sensorineural hearing loss (SSNHL) is a severe disease affecting more than 200,000 patients per year WHAT IS SSNHL? The sudden onset of a significant hearing loss due to dysfunction of the cells of the cochlea and central auditory structures. Hearing loss develops over less than 72 hrs, heari
Slide 48: AUDIBLE-S phase 2 design
SSNHL AUDIBLE-S phase 2 design A Phase 2b, Multicenter, Randomized, Controlled, Double-blind Study to Evaluate the Efficacy of SENS-401 to Treat Patients with Severe to Profound Sudden Sensorineural Hearing Loss 50 clinical sites globally 1 Primary endpoint +/- oral corticosteroids Audiometry 15 dB
Slide 49: SENS-401 induces complete PTA recovery in 50% of patients
SSNHL SENS-401 induces complete PTA recovery in 50% of patients COMPLETE PTA RECOVERY 60.0% * p=0.046 50.0% 40.0% Complete PTA SENS-401 30.0% Placebo recovery (n/n total) (2 doses pooled*) 20.0% Day 28 9/28 25/49 10.0% Day 84 8/26 22/40 0.0% DAY 28 DAY 84 *As SENS-401 plasmatic concentration is simi
Slide 50: Phase 2 results summary
SSNHL Phase 2 results summary Complete PTA recovery is achieved in 50% of the SENS-401 treated patients. SENS-401 shows a clinically meaningful and statistically significant effect on PTA change (at least 10 dB) over time in a large homogeneous idiopathic population of patients treated with corticos